UAE market indices at close

Friday, 6 November 2026 ·

Dubai Financial Market Index

6,025.55

-17.10 / -0.28%

Exchange summary (trading totals unavailable)

Trading volume
—
Traded value (AED)
—
Number of trades
—

FTSE ADX General Index (FADGI)

9,392.60

-127.22 / -1.34%

Exchange summary (trading totals unavailable)

Trading volume
—
Traded value (AED)
—
Number of trades
—

Dated session snapshot, not a live feed. Whole-exchange trading totals were not supplied for this session.

GoFinsa

Welcome to GoFinsa!

Gulf Pharmaceutical Industries P.S.C.

JULPHAR
0.93 AED
Change: -2.11%
Latest available price · 2026-11-06

JULPHAR — price data

Supplied closing session:

Session close, as supplied
0.9300 AED
6 November session change
-2.11%
Session volume (shares)
535.58K (rounded)
Session relative volume
0.51

Retained financial metrics — not refreshed by this close

Financial reference date: 2026-10-19

Reference market capitalization
1.13e+09 AED
Reference trailing P/E
13.71
Reference trailing EPS
0.07 AED
Reference dividend yield
0%
Retained analyst sentiment
غير متوفر

Dated, user-supplied session data, not live prices or independently verified official closes. K/M volumes retain source rounding. Financial metrics and GFSI ratings have not been recalculated.

Gulf Pharmaceutical Industries P.S.C. stock (JULPHAR) price and technical analysis

GoFinsa tracks Gulf Pharmaceutical Industries P.S.C. under symbol JULPHAR, with the latest available price at 0.93 AED. This page includes multi-timeframe charts, technical analysis and related market news.

The session change is -2.11%.

Market data source: 2026-11-06 session close, as supplied · Latest available update: 2026-11-06 · Delayed market data

Gulf Pharmaceutical Industries (Julphar) (JULPHAR) Stock: Financials, Valuation and Risks | GoFinsa

Company financial and price indicators require reconciliation with official filings. Unverified financial figures are not displayed.

Company identity and business model

The material identifies Gulf Pharmaceutical Industries (Julphar) under ticker JULPHAR on ADX. The company's economic exposure is best approached through pharmaceutical manufacturing, registrations and distribution. Before assessing returns, readers should distinguish contractual revenues from accounting gains and clarify the legal reporting entity and principal operating subsidiaries. A company name or sector label alone cannot establish revenue composition, territorial footprint or ownership. Investors should verify the latest annual report, segment notes and corporate disclosures before relying on a headline story about expansion. A robust business model should translate customers, contracts or products into repeatable cash generation instead of depending solely on a favorable equity-market valuation.

Sector dynamics and competitive position

Competition and growth in this line of business depend on factors that are not captured by the stock chart. For Gulf Pharmaceutical Industries (Julphar), the analysis should prioritize regulatory approvals, factory utilization and product-mix. A stronger position would generally show sustainable customer relationships, defensible capabilities and the ability to protect unit margins when input prices rise. A weaker position may require higher investment simply to maintain sales. Market share, scale and brand strengths should be documented in primary disclosures; no precise market-share claim is made here. The relevant comparison set consists of firms with similar activities, accounting structures and financial leverage, not merely companies whose share prices look comparable.

Reference market snapshot and its limitations

These are a historical snapshot rather than current prices. The reported figures are neither independently validated against exchange tapes nor an assurance that the last trade occurred on the snapshot date. Comparing this price with any newer company release requires adjustment for stock splits, capital increases, special distributions and changes in share count. A sensible valuation begins by confirming price, outstanding shares and date in a common period. Readers should not equate a quoted last price with an executable bid or ask in a thinly traded security.

Revenue, profitability and quality of earnings

Company financial and price indicators require reconciliation with official filings. Unverified financial figures are not displayed.

Balance sheet, liquidity and debt

A balance-sheet assessment should establish the level and maturity of borrowings, cash reserves, committed capital expenditure and contingent liabilities. The key question is whether working capital and cash from operations can fund ordinary activity and near-term commitments in a less favorable market. The relative importance of debt, reserves and customer receivables varies across industries; use sector-appropriate ratios rather than applying a generic debt threshold. For JULPHAR, available source text does not independently establish covenant headroom, secured borrowing or maturity concentration. Any claim that financing is safe or risky in absolute terms requires the underlying notes to the accounts.

Cash generation and capital allocation

Accounting profit is not the same as distributable cash. Assess operating cash after movements in receivables, inventory and payables, followed by maintenance and expansion spending. For a business exposed to pharmaceutical manufacturing, registrations and distribution, the distinction between cash received and profit recognized can be especially important. Capital allocation should also include acquisitions, disposal proceeds, shareholder distributions and changes in leverage. Sustainable reinvestment may create more long-term value than a one-off exceptional return, but only if incremental projects earn more than their cost of capital. Review board approvals and audited cash-flow records instead of estimating payout capacity from the share price alone.

Earnings per share and valuation multiples

Company financial and price indicators require reconciliation with official filings. Unverified financial figures are not displayed.

Dividends and total shareholder return

Company financial and price indicators require reconciliation with official filings. Unverified financial figures are not displayed.

Share performance and technical interpretation

Price changes describe what the market paid over specific observation windows; they do not explain why operations improved or deteriorated. The source snapshot contains performance and technical signals, but these are dated and may depend on changing indicator settings. To interpret JULPHAR, separate short-term momentum from liquidity and fundamental developments, then check volume, spread and the impact of announcements. A technical 'buy' or 'sell' summary is not a tested forecast and can conflict with the long-term fundamental picture. This dossier does not invent a current support, resistance or target price without a contemporaneous chart and reproducible methodology.

Key company-specific risks

The most material scenario risks for a company exposed to pharmaceutical manufacturing, registrations and distribution include quality incidents, price controls and working capital. They interact with broad market risks such as higher financing costs, slower economic activity and weaker risk appetite. Concentration in counterparties, assets or countries may magnify an otherwise modest operating shock. For Gulf Pharmaceutical Industries (Julphar), a prudent review should ask what would happen to operating cash, covenants and capital spending in a prolonged weak-demand scenario. The supplied snapshot cannot quantify all of these effects; sensitivity estimates and exposure concentrations should be taken from the issuer's published financial notes, not inferred from a moving average.

Practical checklist before buying or selling

First confirm that JULPHAR and the issuer name match the exchange listing, then locate the latest audited accounts and any intervening quarterly releases. Second, reconcile the balance sheet and dividends with disclosed cash flows. Third, evaluate regulatory approvals, factory utilization and product-mix against comparable listed businesses. Fourth, check corporate actions and whether the quote is timely and liquid enough for the intended order size. Fifth, decide in advance how much capital can be lost without affecting necessary spending. No single P/E ratio, headline distribution yield or analyst opinion can replace this process. The market data in this dossier are dated reference inputs only.

What would change the investment thesis?

A constructive fundamental thesis requires repeatable cash generation, credible management execution and an attractive valuation relative to identifiable risks. An adverse thesis might develop if quality incidents, price controls and working capital worsen or the underlying financial releases contradict expected cash generation. For Gulf Pharmaceutical Industries (Julphar), a monitored thesis should define objective milestones, such as audited cash conversion, relevant operating volumes and financing terms, then revisit them after each disclosure. Neither a recent rally nor a recent decline is sufficient to establish fair value. Potential upside and downside remain uncertain; the research is educational and not individualized financial advice.

Sources, methodology and data freshness

Company identity and the numeric snapshot above come from information supplied for this batch, rather than an independent exchange data feed. Primary-source confirmation should use the issuer's latest investor-relations publications, exchange filings and regulatory notices. The supplied web domain (julphar.net) is a candidate company website, not a certification that every figure on this page is verified. Where a conflict arises, use the dated official disclosure and record the accounting period. The price shown here is not refreshed automatically and is not an official closing price verified by GoFinsa. Editorial sign-off must precede publication.

المصادر والمراجع

أسئلة شائعة عن الشركة

Where is JULPHAR listed?

The supplied company information places JULPHAR on ADX. Confirm the active symbol and share class at the exchange.

What reference share price is shown for JULPHAR?

Company financial and price indicators require reconciliation with official filings. Unverified financial figures are not displayed.

What business issues matter most for Gulf Pharmaceutical Industries (Julphar)?

The research focuses on regulatory approvals, factory utilization and product-mix, as well as balance-sheet and cash-flow quality.

How should investors read the P/E ratio?

The supplied P/E is 14.29; it must be checked against reported earnings, one-off items and any changes in capital.

Does JULPHAR guarantee dividends?

Company financial and price indicators require reconciliation with official filings. Unverified financial figures are not displayed.

Is this a buy recommendation?

No. It is company research using dated reference data, and it does not assess an individual investor’s suitability.

What should be checked before investing?

Official exchange filings, recent financial statements, risk disclosures, liquidity, and whether a broker provides access to the specific listed security.

Frequently asked questions about Gulf Pharmaceutical Industries P.S.C. (JULPHAR)

What is the price of Gulf Pharmaceutical Industries P.S.C. (JULPHAR)?

The latest price available in GoFinsa data is 0.93 AED. Price status may be live or delayed depending on the market and data provider.

What does the technical analysis for Gulf Pharmaceutical Industries P.S.C. (JULPHAR) show?

There is currently insufficient data to produce technical analysis for this instrument.

What is the GoFinsa.com General Index for Gulf Pharmaceutical Industries P.S.C.?

The GoFinsa.com General Index is currently unavailable for this instrument.